[go: up one dir, main page]

RU2013101969A - Средство для лечения фиброза почек - Google Patents

Средство для лечения фиброза почек Download PDF

Info

Publication number
RU2013101969A
RU2013101969A RU2013101969/15A RU2013101969A RU2013101969A RU 2013101969 A RU2013101969 A RU 2013101969A RU 2013101969/15 A RU2013101969/15 A RU 2013101969/15A RU 2013101969 A RU2013101969 A RU 2013101969A RU 2013101969 A RU2013101969 A RU 2013101969A
Authority
RU
Russia
Prior art keywords
extracellular matrix
kidney
activity
producing cells
retinoid
Prior art date
Application number
RU2013101969/15A
Other languages
English (en)
Other versions
RU2635460C2 (ru
Inventor
Еширо НИИТСУ
Кейко КАДЖИВАРА
Ясунобу ТАНАКА
Мийоно МИЯЗАКИ
Original Assignee
Нитто Денко Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нитто Денко Корпорейшн filed Critical Нитто Денко Корпорейшн
Publication of RU2013101969A publication Critical patent/RU2013101969A/ru
Application granted granted Critical
Publication of RU2635460C2 publication Critical patent/RU2635460C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1. Носитель для доставки вещества к продуцирующим внеклеточный матрикс клеткам в почке, отличающийся тем, что он содержит ретиноид в качестве агента, нацеливающего на продуцирующие внеклеточный матрикс клетки в почке.2. Носитель по п.1, отличающийся тем, что ретиноид содержит ретинол.3. Носитель по п.1 или 2, отличающийся тем, что он имеет форму липосомы и мольное отношение ретиноида и липида, содержавшегося в липосоме, составляет от 8:1 до 1:4.4. Фармацевтическая композиция для лечения фиброза почек, отличающаяся тем, что она содержит носитель по любому из пп.1-3 и лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке.5. Фармацевтическая композиция по п.4, отличающаяся тем, что лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке выбирается из группы, состоящей из ингибитора активности или продуцирования PAI-1, ингибитора клеточной активности, ингибитора роста, индуктора апоптоза и молекулы РНКи, рибозима, антисмысловой нуклеиновой кислоты или ДНК/РНК химерного полинуклеотида, которые нацелены по меньшей мере на одно из молекул, составляющих внеклеточный матрикс, или молекул, вовлеченных в продуцирование или секрецию молекул, составляющих внеклеточный матрикс, или вектора, экспрессирующий их.6. Фармацевтическая композиция по п.4, отличающаяся тем, что лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток представляет собой ингибитор HSP47.7. Фармацевтическая композиция по любому из пп.4-6, отличающаяся тем, что лекарственное средство и носитель смешиваются в месте леч�

Claims (10)

1. Носитель для доставки вещества к продуцирующим внеклеточный матрикс клеткам в почке, отличающийся тем, что он содержит ретиноид в качестве агента, нацеливающего на продуцирующие внеклеточный матрикс клетки в почке.
2. Носитель по п.1, отличающийся тем, что ретиноид содержит ретинол.
3. Носитель по п.1 или 2, отличающийся тем, что он имеет форму липосомы и мольное отношение ретиноида и липида, содержавшегося в липосоме, составляет от 8:1 до 1:4.
4. Фармацевтическая композиция для лечения фиброза почек, отличающаяся тем, что она содержит носитель по любому из пп.1-3 и лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке.
5. Фармацевтическая композиция по п.4, отличающаяся тем, что лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке выбирается из группы, состоящей из ингибитора активности или продуцирования PAI-1, ингибитора клеточной активности, ингибитора роста, индуктора апоптоза и молекулы РНКи, рибозима, антисмысловой нуклеиновой кислоты или ДНК/РНК химерного полинуклеотида, которые нацелены по меньшей мере на одно из молекул, составляющих внеклеточный матрикс, или молекул, вовлеченных в продуцирование или секрецию молекул, составляющих внеклеточный матрикс, или вектора, экспрессирующий их.
6. Фармацевтическая композиция по п.4, отличающаяся тем, что лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток представляет собой ингибитор HSP47.
7. Фармацевтическая композиция по любому из пп.4-6, отличающаяся тем, что лекарственное средство и носитель смешиваются в месте лечения или поблизости от него.
8. Набор для получения фармацевтической композиции по любому из пп.4-7, отличающийся тем, что он содержит один или более контейнеров, которые содержат либо по отдельности, либо в комбинации лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке, ретиноид и при необходимости составляющее носитель вещество, отличное от ретиноида.
9. Способ получения носителя для доставки вещества к продуцирующим внеклеточный матрикс клеткам в почке, отличающийся тем, что он содержит стадию введения ретиноида в качестве агента, нацеливающего на продуцирующие внеклеточный матрикс клетки.
10. Способ получения фармацевтической композиции для лечения фиброза почек, отличающийся тем, что он содержит стадию введения ретиноида в качестве агента, нацеливающего на продуцирующие внеклеточный матрикс клетки в почке, и лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке в качестве активного ингредиента.
RU2013101969A 2010-06-17 2011-06-17 Средство для лечения фиброза почек RU2635460C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010-138070 2010-06-17
JP2010138070 2010-06-17
PCT/JP2011/063910 WO2011158933A1 (ja) 2010-06-17 2011-06-17 腎線維症処置剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017136720A Division RU2711531C2 (ru) 2010-06-17 2011-06-17 Средство для лечения фиброза почек

Publications (2)

Publication Number Publication Date
RU2013101969A true RU2013101969A (ru) 2014-07-27
RU2635460C2 RU2635460C2 (ru) 2017-11-13

Family

ID=45348325

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017136720A RU2711531C2 (ru) 2010-06-17 2011-06-17 Средство для лечения фиброза почек
RU2013101969A RU2635460C2 (ru) 2010-06-17 2011-06-17 Средство для лечения фиброза почек

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2017136720A RU2711531C2 (ru) 2010-06-17 2011-06-17 Средство для лечения фиброза почек

Country Status (12)

Country Link
US (2) US20130136789A1 (ru)
EP (1) EP2583691B1 (ru)
JP (2) JP2012020995A (ru)
KR (1) KR101967868B1 (ru)
CN (1) CN102933233A (ru)
AU (1) AU2011266057B2 (ru)
CA (1) CA2802414C (ru)
ES (1) ES2712086T3 (ru)
IN (1) IN2013CN00342A (ru)
RU (2) RU2711531C2 (ru)
TW (1) TWI549691B (ru)
WO (1) WO2011158933A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
CA3114497A1 (en) 2013-01-18 2014-07-24 Cornell University Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists
US9976142B2 (en) 2014-04-02 2018-05-22 Nitto Denko Corporation Targeting molecule and a use thereof
JP6480467B2 (ja) 2014-04-07 2019-03-13 日東電工株式会社 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ
CN105597085A (zh) * 2015-12-17 2016-05-25 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21在治疗肾纤维化中的应用
JP6833456B2 (ja) * 2016-11-02 2021-02-24 日東電工株式会社 皮膚線維症処置剤
KR102352489B1 (ko) 2019-12-09 2022-01-18 전남대학교산학협력단 소수성 개질된 글리콜 키토산 나노입자 및 이를 이용한 신장 표적화 약물 전달체
CN114994317B (zh) * 2022-04-15 2025-10-28 宁波市杭州湾医院 金属蛋白酶adamts4在制备早期肝纤维化药物中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238924A (en) 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6334999B1 (en) * 1999-08-27 2002-01-01 Research Development Foundation Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
BR0006556A (pt) * 2000-12-28 2002-09-17 Apsen Farmaceutica S A Composição farmacêutica para uso tópico à base de corticosteróide para tratamento de fimose
IL143366A0 (en) 2001-05-24 2002-04-21 Harasit Medical Res Services & Treatment of renal fibrosis
JP2004043459A (ja) 2002-05-24 2004-02-12 Sumitomo Pharmaceut Co Ltd ＴＧＦ−β阻害活性を有する低分子化合物からなる医薬
EP1454625A1 (en) 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
WO2005107463A1 (en) 2004-05-03 2005-11-17 University Of Virginia Patent Foundation Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
KR100613342B1 (ko) 2004-12-16 2006-08-21 동부일렉트로닉스 주식회사 반도체 소자 및 그 제조방법
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
PT2730277T (pt) * 2004-12-22 2020-04-21 Nitto Denko Corp Veículo de fármaco e kit de veículo de fármaco para a inibição da fibrose
JP2007099641A (ja) 2005-09-30 2007-04-19 Tsumura & Co インドールキノキサリン類化合物、その製造方法およびそれを用いた医薬組成物
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
JP2009292725A (ja) 2006-09-01 2009-12-17 Stelic Institute Of Regenerative Medicine 腎疾患改善剤
TWI407971B (zh) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
JP2009007258A (ja) 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd Ｐａｉ−１産生抑制作用を有する３−アニリノ−２−シクロアルケノン誘導体
JP2009029750A (ja) 2007-07-27 2009-02-12 Kowa Co アリールプロパン誘導体を有効成分とする糖化最終産物形成阻害剤
CA2698812A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
JP2009178143A (ja) 2008-02-01 2009-08-13 Stelic Institute Of Regenerative Medicine 脂肪性肝炎−肝癌モデル動物
CN102159247A (zh) * 2008-07-30 2011-08-17 日东电工株式会社 药物载体
WO2010029760A1 (en) * 2008-09-12 2010-03-18 Nitto Denko Corporation Imaging agents of fibrotic diseases
JP2010077101A (ja) 2008-09-29 2010-04-08 Toray Ind Inc 腎線維症の治療剤又は予防剤
ES2562499T3 (es) * 2009-12-09 2016-03-04 Nitto Denko Corporation Modulación de la expresión de HSP47
KR102038300B1 (ko) * 2011-06-08 2019-10-31 닛토덴코 가부시키가이샤 표적 약물 전달체 및 ｓｉＲＮＡ 활성을 증가시키는 화합물

Also Published As

Publication number Publication date
KR20130121813A (ko) 2013-11-06
RU2635460C2 (ru) 2017-11-13
TWI549691B (zh) 2016-09-21
US20130136789A1 (en) 2013-05-30
ES2712086T3 (es) 2019-05-09
JP5873589B2 (ja) 2016-03-01
CA2802414C (en) 2018-01-09
AU2011266057A1 (en) 2013-01-10
JP2012020995A (ja) 2012-02-02
TW201204389A (en) 2012-02-01
IN2013CN00342A (ru) 2015-07-03
EP2583691B1 (en) 2019-01-16
RU2711531C2 (ru) 2020-01-17
JP2015155459A (ja) 2015-08-27
CA2802414A1 (en) 2011-12-22
AU2011266057B2 (en) 2014-12-04
WO2011158933A1 (ja) 2011-12-22
EP2583691A1 (en) 2013-04-24
EP2583691A4 (en) 2016-04-27
RU2017136720A3 (ru) 2019-02-08
KR101967868B1 (ko) 2019-08-19
RU2017136720A (ru) 2019-02-08
CN102933233A (zh) 2013-02-13
US20150259683A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
RU2013101969A (ru) Средство для лечения фиброза почек
RU2015105524A (ru) Терапевтический агент, применяемый при пневмофиброзе
Olejarz et al. Exosomes in angiogenesis and anti-angiogenic therapy in cancers
Smith et al. Clinical applications of short non-coding RNA-based therapies in the era of precision medicine
Sadakierska-Chudy MicroRNAs: diverse mechanisms of action and their potential applications as cancer epi-therapeutics
Dang et al. The role of hypoxia-induced miR-210 in cancer progression
Costa et al. MicroRNAs as molecular targets for cancer therapy: on the modulation of microRNA expression
Gozuacik et al. Autophagy-regulating microRNAs and cancer
RU2014101547A (ru) Апоптоз-индуцирующее средство
US8906874B2 (en) Bi-functional shRNA targeting Stathmin 1 and uses thereof
EA202191313A1 (ru) Композиции на основе липидных наночастиц
Prakash et al. Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals
RU2011112645A (ru) Средство для лечения миелофиброза
WO2012170957A8 (en) Retinoid-liposomes for enhancing modulation of hsp47 expression
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
Wong et al. Potential miRNAs for miRNA-based therapeutics in breast cancer
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
Alvarez et al. Towards microRNA-based therapeutics for diabetic nephropathy
AU2012358181A8 (en) Compositions and methods for the delivery of biologically active RNAs
Ghasemi et al. Tumor-derived microvesicles: the metastasomes
Syed et al. Exosomal and non-exosomal microRNAs: new kids on the block for cancer therapy
Wu et al. Induction of osteogenic differentiation of stem cells via a lyophilized microRNA reverse transfection formulation on a tissue culture plate
Kowara et al. Therapies targeted at non-coding RNAs in prevention and limitation of myocardial infarction and subsequent cardiac remodeling—current experience and perspectives